Molecular Networking As a Drug Discovery, Drug Metabolism, and Precision Medicine Strategy

Trends in Pharmacological Sciences

Volumn 38, Issue 2, 2017, Pages 143-154

  Quinn, Robert A ^a   Nothias, Louis Felix ^a   Vining, Oliver ^b   Meehan, Michael ^a   Esquenazi, Eduardo ^b   Dorrestein, Pieter C ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Sirenas   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

mass spectrometry; metabolomics; molecular networking

Indexed keywords

ANTIBODY DRUG CONJUGATE; ARTEMISININ; AURISTATIN; AZITHROMYCIN; COLUMBAMIDE DERIVATIVE; DOLASTATIN 10; IVACAFTOR; MALEVAMIDE D; NATURAL PRODUCT; POLYKETIDE; RETIMYCIN A; SALBUTAMOL; SMD 5041; SPHONGONUCLEOSIDE DERIVATIVE; SYMPLOSTATIN 1; SYMPLOSTATIN 3; TRIMETHOPRIM; UNCLASSIFIED DRUG; VITROPROCINE DERIVATIVE; DRUG;

CYSTIC FIBROSIS; DRUG DEVELOPMENT; DRUG ISOLATION; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; HUMAN; LIQUID CHROMATOGRAPHY; METABOLOMICS; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; SOFTWARE; TANDEM MASS SPECTROMETRY; METABOLISM; PROCEDURES;

DRUG DISCOVERY; HUMANS; METABOLOMICS; PHARMACEUTICAL PREPARATIONS; PRECISION MEDICINE; TANDEM MASS SPECTROMETRY;

EID: 85006817466     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.10.011     Document Type: Review

References (78)

1. 1 Horning, E.C., Horning, M.G., Metabolic profiles: chromatographic methods for isolation and characterization of a variety of metabolites in man. Methods Med. Res. 12 (1970), 369–371.
2. 2 Pauling, L., et al. Quantitative analysis of urine vapor and breath by gas–liquid partition chromatography. Proc. Natl. Acad. Sci. U. S. A. 68 (1971), 2374–2376.
3. 3 Balog, J., et al. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci. Transl. Med., 5, 2013, 194ra93.
4. 4 da Silva, R.R., et al. Illuminating the dark matter in metabolomics. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 12549–12550.
5. 5 Watrous, J., et al. Mass spectral molecular networking of living microbial colonies. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 1743–1752.
6. 6 Wang, M., et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat. Biotechnol. 34 (2016), 828–837.
7. 7 Guthals, A., et al. The spectral networks paradigm in high throughput mass spectrometry. Mol. Biosyst. 8 (2012), 2535–2544.
8. 8 Traxler, M.F., Kolter, R., A massively spectacular view of the chemical lives of microbes. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 10128–10129.
9. 9 Moree, W.J., et al. Interkingdom metabolic transformations captured by microbial imaging mass spectrometry. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 13811–13816.
10. 10 Vizcaino, M.I., Crawford, J.M., Secondary metabolic pathway-targeted metabolomics. Methods Mol. Biol. 1401 (2016), 175–195.
11. 11 Li, D., et al. Navigating natural variation in herbivory-induced secondary metabolism in coyote tobacco populations using MS/MS structural analysis. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E4147–E4155.
12. 12 Edlund, A., et al. Meta-omics uncover temporal regulation of pathways across oral microbiome genera during in vitro sugar metabolism. ISME J. 9 (2015), 2605–2619.
13. 13 Altschul, S.F., et al. Basic Local Alignment Search Tool. J. Mol. Biol. 215 (1990), 403–410.
14. 14 Tautenhahn, R., et al. XCMS Online: a web-based platform to process untargeted metabolomic data. Anal. Chem. 84 (2012), 5035–5039.
15. 15 Giacomoni, F., et al. Workflow4Metabolomics: a collaborative research infrastructure for computational metabolomics. Bioinformatics 31 (2015), 1493–1495.
16. 16 Xia, J., et al. MetaboAnalyst 3.0 – making metabolomics more meaningful. Nucleic Acids Res. 43 (2015), W251–W257.
17. 17 Johnson, C.H., et al. Bioinformatics: the next frontier of metabolomics. Anal. Chem. 87 (2015), 147–156.
18. 18 Misra, B.B., van der Hooft, J.J.J., Updates in metabolomics tools and resources: 2014-2015. Electrophoresis 37 (2016), 86–110.
19. 19 Alonso, A., et al. Analytical methods in untargeted metabolomics: state of the art in 2015. Front. Bioeng. Biotechnol., 3, 2015, 23.
20. 20 Frank, A.M., et al. Spectral archives: extending spectral libraries to analyze both identified and unidentified spectra. Nat. Methods 8 (2011), 587–591.
21. 21 Frank, A.M., et al. Clustering millions of tandem mass spectra. J. Proteome Res. 7 (2008), 113–122.
22. 22 Shannon, P., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003), 2498–2504.
23. 23 Nguyen, D.D., et al. MS/MS networking guided analysis of molecule and gene cluster families. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E2611–E2620.
24. 24 Garg, N., et al. Mass spectral similarity for untargeted metabolomics data analysis of complex mixtures. Int. J. Mass Spectrom. 377 (2014), 719–727.
25. 25 Yang, J.Y., et al. Molecular networking as a dereplication strategy. J. Nat. Prod. 76 (2013), 1686–1699.
26. 26 Cragg, G.M., Newman, D.J., Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta 1830 (2013), 3670–3695.
27. 27 Liaw, C-C., et al. Vitroprocines, new antibiotics against Acinetobacter baumannii, discovered from marine Vibrio sp. QWI-06 using mass-spectrometry-based metabolomics approach. Sci. Rep., 5, 2015, 12856.
28. 28 Bertin, M.J., et al. Spongosine production by a Vibrio harveyi strain associated with the sponge Tectitethya crypta. J. Nat. Prod. 78 (2015), 493–499.
29. 29 Liu, W-T., et al. MS/MS-based networking and peptidogenomics guided genome mining revealed the stenothricin gene cluster in Streptomyces roseosporus. J. Antibiot. (Tokyo) 67 (2014), 99–104.
30. 30 Kleigrewe, K., et al. Combining mass spectrometric metabolic profiling with genomic analysis: a powerful approach for discovering natural products from cyanobacteria. J. Nat. Prod. 78 (2015), 1671–1682.
31. 31 Duncan, K.R., et al. Molecular networking and pattern-based genome mining improves discovery of biosynthetic gene clusters and their products from Salinispora species. Chem. Biol. 22 (2015), 460–471.
32. 32 Okada, B.K., et al. Mapping the trimethoprim-induced secondary metabolome of Burkholderia thailandensis. ACS Chem. Biol. 11 (2016), 2124–2130.
33. 33 Perez, H.L., et al. Antibody–drug conjugates: current status and future directions. Drug Discov. Today 19 (2014), 869–881.
34. 34 Pettit, G.R., et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc. 109 (1987), 6883–6885.
35. 35 Harrigan, G.G., et al. Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J. Nat. Prod. 61 (1998), 1075–1077.
36. 36 Luesch, H., et al. Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452. J. Nat. Prod. 65 (2002), 16–20.
37. 37 Horgen, F.D., et al. Malevamide D: isolation and structure determination of an isodolastatin H analogue from the marine cyanobacterium Symploca hydnoides. J. Nat. Prod. 65 (2002), 487–491.
38. 38 Harvey, A.L., et al. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov. 14 (2015), 111–129.
39. 39 Kim, E., et al. Reinvigorating natural product combinatorial biosynthesis with synthetic biology. Nat. Chem. Biol. 11 (2015), 649–659.
40. 40 Paddon, C.J., Keasling, J.D., Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat. Rev. Microbiol. 12 (2014), 355–367.
41. 41 Guengerich, F.P., Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8 (2006), E101–E111.
42. 42 Wallace, B.D., et al. Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol. 22 (2015), 1238–1249.
43. 43 Spanogiannopoulos, P., et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14 (2016), 273–287.
44. 44 Haiser, H.J., et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341 (2013), 295–298.
45. 45 Prakash, C., et al. Analytical strategies for identifying drug metabolites. Mass Spectrom. Rev. 26 (2007), 340–369.
46. 46 Kind, T., Fiehn, O., Advances in structure elucidation of small molecules using mass spectrometry. Bioanal. Rev. 2 (2010), 23–60.
47. 47 Kostiainen, R., et al. Liquid chromatography/atmospheric pressure ionization–mass spectrometry in drug metabolism studies. J. Mass Spectrom. 38 (2003), 357–372.
48. 48 Ma, S., Zhu, M., Recent advances in applications of liquid chromatography–tandem mass spectrometry to the analysis of reactive drug metabolites. Chem. Biol. Interact. 179 (2009), 25–37.
49. 49 Tolonen, A., et al. Liquid chromatography–mass spectrometry in in vitro drug metabolite screening. Drug Discov. Today 14 (2009), 120–133.
50. 50 Quinn, R.A., et al. Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome. ISME J. 10 (2015), 1483–1498.
51. 51 Lynch, S.V., Bruce, K.D., The cystic fibrosis airway microbiome. Cold Spring Harb. Perspect. Med., 3, 2013, a009738.
52. 52 Robertson, S.M., et al. Clinical drug–drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J. Clin. Pharmacol. 55 (2015), 56–62.
53. 53 Bouslimani, A., et al. Molecular cartography of the human skin surface in 3D. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E2120–E2129.
54. 54 Facchini, F., et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266 (1991), 3008–3011.
55. 55 Matsuura, F., et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47 (1998), 929–933.
56. 56 Yoo, T.W., et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ. J. 69 (2005), 928–933.
57. 57 Chace, D.H., et al. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin. Chem. 49 (2003), 1797–1817.
58. 58 Voge, N.V., et al. Metabolomics-based discovery of small molecule biomarkers in serum associated with dengue virus infections and disease outcomes. PLoS Negl. Trop. Dis., 10, 2016, e0004449.
59. 59 Whiteson, K.L., et al. Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. ISME J. 8 (2014), 1247–1258.
60. 60 Singhal, N., et al. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front. Microbiol., 6, 2015, 791.
61. 61 Quinn, R.A., et al. From sample to multi-omics conclusions in under 48 hours. mSystems, 1, 2016, e00038-16.
62. 62 Hunter, R.C., et al. Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. Am. J. Respir. Cell Mol. Biol. 47 (2012), 738–745.
63. 63 Singh, P.K., et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407 (2000), 762–764.
64. 64 Lau, S.K.P., et al. Identification of specific metabolites in culture supernatant of Mycobacterium tuberculosis using metabolomics: exploration of potential biomarkers. Emerg. Microbes Infect., 4, 2015, e6.
65. 65 Vizcaino, M.I., Crawford, J.M., The colibactin warhead crosslinks DNA. Nat. Chem. 7 (2015), 411–417.
66. 66 Collins, F.S., Varmus, H., A new initiative on precision medicine. N. Engl. J. Med. 372 (2015), 793–795.
67. 67 Quinn, R.A., et al. Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease. PeerJ, 4, 2016, e2174.
68. 68 Böcker, S., Dührkop, K., Fragmentation trees reloaded. J. Cheminform., 8, 2016, 5.
69. 69 Dührkop, K., et al. Searching molecular structure databases with tandem mass spectra using CSI:FingerID. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 12580–12585.
70. 70 Ruttkies, C., et al. MetFrag relaunched: incorporating strategies beyond in silico fragmentation. J. Cheminform., 8, 2016, 3.
71. 71 Allard, P-M., et al. Integration of molecular networking and in-silico MS/MS fragmentation for natural products dereplication. Anal. Chem. 88 (2016), 3317–3323.
72. 72 Allen, F., et al. CFM-ID: a web server for annotation, spectrum prediction and metabolite identification from tandem mass spectra. Nucleic Acids Res. 42 (2014), W94–W99.
73. 73 Greaves, J., Roboz, J., Mass Spectrometry for the Novice. 2013, CRC Press.
74. 74 Vuckovic, D., Current trends and challenges in sample preparation for global metabolomics using liquid chromatography–mass spectrometry. Anal. Bioanal. Chem. 403 (2012), 1523–1548.
75. 75 Bylda, C., et al. Recent advances in sample preparation techniques to overcome difficulties encountered during quantitative analysis of small molecules from biofluids using LC-MS/MS. Analyst, 139, 2014, 2265.
76. 76 Wehrens, R., et al. Improved batch correction in untargeted MS-based metabolomics. Metabolomics, 12, 2016, 88.
77. 77 Koal, T., Deigner, H-P., Challenges in mass spectrometry based targeted metabolomics. Curr. Mol. Med. 10 (2010), 216–226.
78. 78 Nothias-Scaglia, L-F., et al. Molecular networks, a comprehensive bioinformatics approach to interpreting tandem mass spectrometry data. Spectra Anal. 307 (2015), 73–78.